TITLE

Tadalafil

PUB. DATE
August 2020
SOURCE
AHFS Consumer Medication Information;Aug2020, p1
SOURCE TYPE
Database
DOC. TYPE
Article
ABSTRACT
Tadalafil (Cialis) is used to treat erectile dysfunction (ED, impotence; inability to get or keep an erection), and the symptoms of benign prostatic hyperplasia (BPH; an enlarged prostate) which include difficulty urinating (hesitation, dribbling, weak stream, and incomplete bladder emptying), painful urination, and urinary frequency and urgency in adult men. Tadalafil (Adcirca) is used to improve the ability to exercise in people with pulmonary arterial hypertension (PAH; high blood pressure in the vessels carrying blood to the lungs, causing shortness of breath, dizziness, and tiredness). Tadalafil is in a class of medications called phosphodiesterase (PDE) inhibitors. It works to treat erectile dysfunction by increasing blood flow to the penis during sexual stimulation. This increased blood flow can cause an erection. Tadalafil treats PAH by relaxing the blood vessels in the lungs to allow blood to flow more easily. If you are taking tadalafil to treat erectile dysfunction, you should know that it does not cure erectile dysfunction or increase sexual desire. Tadalafil does not prevent pregnancy or the spread of sexually transmitted diseases such as human immunodeficiency virus (HIV).
ACCESSION #
78170069

 

Related Articles

  • The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction. Gacci, Mauro; Salvi, Matteo; Sebastianelli, Arcangelo; Vignozzi, Linda; Corona, Giovanni; McVary, Kevin T.; Kaplan, Steven A.; Maggi, Mario; Carini, Marco; Oelke, Matthias // Research & Reports in Urology;Apr2013, Vol. 5, p99 

    A strong and independent association between lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) and erectile dysfunction (ED) has been widely evidenced in several clinical epidemiologic studies. Preclinical animal models have provided a great deal of information...

  • Erectile dysfunction drug approved to treat BPH symptoms.  // Mayo Clinic Health Letter;Apr2012, Vol. 30 Issue 4, p4 

    The article reports that the U.S. Food and Drug Administration has approved tadalafil (Cialis) as a drug for the treatment of urinary symptoms of benign prostatic hyperplasia (BHP).

  • Treatment options in benign prostate hyperplasia associated with lower urinary tract symptoms. Atan, Ali; Tuncel, Altuğ // Turkish Journal of Urology;Dec2012, Vol. 38 Issue 4, p228 

    Benign prostatic hyperplasia is a common cause of lower urinary tract symptoms. Men who are treated for benign prostatic hyperplasia potentially reduce their lifetime risk of acute urinary retention and the need for benign prostatic hyperplasia-related surgery. In this review, the treatment...

  • Hospital San Lucas has green light for enlarged prostate-related treatment. DÍAZ, MARIO BELAVAL // Caribbean Business;2/19/2015, Vol. 43 Issue 6, pS2 

    The article reports on the GreenLight Laser Therapy, a non-invasive surgical treatment introduced by the Hospital San Lucas (HSL) on patients with enlarged prostate or benign prostatic hyperplasia in Ponce, Puerto Rico. It states that the GreenLight Laser Therapy can reduce surgical side-effects...

  • Management of Benign Prostatic Hyperplasia: Role of Phosphodiesterase-5 Inhibitors. Gacci, M.; Carini, M.; Salvi, M.; Sebastianelli, A.; Vignozzi, L.; Corona, G.; Maggi, M.; McVary, K.; Kaplan, S.; Oelke, M.; Serni, S. // Drugs & Aging;Jun2014, Vol. 31 Issue 6, p425 

    Several studies have highlighted a strong association between benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS) and erectile dysfunction (ED), particularly in elderly men. Many epidemiological trials, such as in vitro and in vivo studies, have reported the emerging role of...

  • The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Umul, Mehmet; Serel, Tekin Ahmet // Turkish Journal of Urology;Dec2013, Vol. 39 Issue 4, p264 

    Phosphodiesterase type-5 (PDE-5) inhibitors are approved as the first line of therapy for the treatment of erectile dysfunction. However, different studies have been performed to study the use of these agents in other areas of urology. There are many studies related to the use of PDE-5...

  • Tadalafil Improves BPH/LUTS.  // Renal & Urology News;Sep2013, Vol. 12 Issue 9, p17 

    The article offers information on the meta-analysis conducted by Chinese investigators which shows the efficacy of a phosphodiesterase type 5 inhibitor Tadalafil in relieving lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).

  • Tadalafil Tablets for BPH (Cialis). Elliott, William T.; Chan, James // Internal Medicine Alert;11/29/2011, Vol. 33 Issue 22, p174 

    The article reports on the approval of Eli Lilly & Co.'s Tadalafil (Cialis) for the treatment of benign prostatic hyperplasia (BPH). It notes the drug's effectivity for men with co-morbid erectile dysfunction and BPH. It also cites the potential of tadalafil to enhance hypotensive effects of...

  • Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations. Alsaikhan, Bader; Alrabeeah, Khalid; Carrier, Serge // International Journal of General Medicine;2014, Vol. 7, p271 

    Lower urinary tract symptoms (LUTS) and erectile dysfunction increase with age. Several studies have identified a true association between these two disorders. Basic research studies have shown a significant decrease in the nitric oxide/cyclic guanosine monophosphate pathway with age that leads...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics